Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 3/20 | 0.39 |
| ▸ | CES1 | P23141 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8373793 | 0.87 | KEAP1 (0.52) | KEAP1NFE2L2CYP3A4CES2CES1 | |
| SCHEMBL10472704 | 0.83 | KEAP1 (0.48) | KEAP1NFE2L2CYP3A4CES2CES1 | |
| SCHEMBL29376622 | 0.83 | KEAP1 (0.52) | KEAP1NFE2L2CYP3A4CES2CES1 | |
| SCHEMBL22972614 | 0.83 | KEAP1 (0.52) | KEAP1NFE2L2CYP3A4CES2CES1 | |
| SCHEMBL2434231 | 0.83 | KEAP1 (0.52) | KEAP1NFE2L2CYP3A4CES2CES1 | |
| SCHEMBL10617307 | 0.82 | KEAP1 (0.47) | KEAP1NFE2L2CYP3A4CES2CES1 | |
| SCHEMBL10626987 | 0.82 | KEAP1 (0.47) | KEAP1NFE2L2CYP3A4KDM4EASPH | |
| Hydrochloric Acid SCHEMBL10563667 | 0.81 | KEAP1 (0.50) | KEAP1NFE2L2CYP3A4CES2CES1 | |
| SCHEMBL8974977 | 0.80 | KEAP1 (0.53) | KEAP1NFE2L2CYP3A4KDM4EASPH | |
| Fluoride SCHEMBL6445071 | 0.79 | KEAP1 (0.47) | KEAP1NFE2L2CES2CES1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0682008-B1 | Substituted 2-chloro-3,4,5-trifluorobenzenes and process for their preparation | CLARIANT GMBH (DE) | 1998-12-30 | — | — | EP | claimed |
| EP-0682008-A1 | Substituted 2-chloro-3,4,5-trifluorobenzenes and process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-11-15 | — | — | EP | claimed |
| JP-4187656-A | — | — | None | — | — | JP | disclosed |
| JP-8040990-A | — | — | None | — | — | JP | disclosed |
| US-7700585-B2 | Derivatives of N-[phenyl(pyrrolidine-2-YL)methyl]benzamide and N-[(azepan-2-YL) phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-04-20 | — | — | US | disclosed |
| WO-2008018639-A2 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-02-14 | — | — | WO | disclosed |
| US-20070208006-A1 | DERIVATIVES OF N-[PHENYL(PYRROLIDINE-2-YL)METHYL]BENZAMIDE AND N-[(AZEPAN-2-YL)PHENYLMETHYL]BENZAMIDE, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-09-06 | — | — | US | disclosed |
| US-7226917-B2 | Derivatives of N-[phenyl(pyrrolidine-2-yl)methyl]benzamide and N-[(azepan-2-yl)phenylmethyl]benzamide, preparation, and use in treatment of schizophrenia | SANOFI-AVENTIS (FR) | 2007-06-05 | — | — | US | disclosed |
| CN-1882534-A | Derivatives of N- [ phenyl (2-pyrrolidinyl) methyl ] benzamide and N- [ (2-azepanyl) phenylmethyl ] benzamide, preparation and therapeutic use thereof | SANOFI AVENTIS (FR) | 2006-12-20 | — | — | CN | disclosed |
| US-20060223802-A1 | Derivatives of N-[phenyl(pyrrolidine-2-yl)methyl]benzamide and N-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2006-10-05 | — | — | US | disclosed |
| EP-0757028-B1 | Process for the preparation of aromatic carbonic acid esters | CLARIANT GMBH (DE) | 1999-12-29 | — | — | EP | disclosed |
| US-5739388-A | Process for the preparation of aromatic compounds by decarboxylation of aromatic carboxylic acids | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-04-14 | — | — | US | disclosed |
| EP-0811601-A1 | Process for the preparation of aromatic carbonic acid esters | Clariant GmbH (DE) | 1997-12-10 | — | — | EP | disclosed |
| EP-0757028-A1 | Process for the preparation of aromatic carbonic acid esters | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-02-05 | — | — | EP | disclosed |
| US-5565612-A | Substituted 2-chloro-3,4,5-trifluorobenzenes and a process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-10-15 | — | — | US | disclosed |
| JP-H0840990-A | SUBSTITUTED 2-CHLORO-3,4,5-TRIFLUOROBENZENE AND ITS PRODUCTION | HOECHST AG | 1996-02-13 | — | — | JP | disclosed |
| US-5481032-A | Process for the preparation of halogenated benzoic acids | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-01-02 | — | — | US | disclosed |
| CN-1112917-A | Substituted 2-chloro-3,4,5-trifluorobenzenes and a process for their preparation | HOECHST AG (DE) | 1995-12-06 | — | — | CN | disclosed |
| EP-0682008-A1 | Substituted 2-chloro-3,4,5-trifluorobenzenes and process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-11-15 | — | — | EP | disclosed |
| JP-H04187656-A | NOVEL 2-CHLORO-3,4,5-TRIFLUOROBENZOIC ACIDS | SEIMI CHEM KK | 1992-07-06 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208006-A1 | DERIVATIVES OF N-[PHENYL(PYRROLIDINE-2-YL)METHYL]BENZAMIDE AND N-[(AZEPAN-2-YL)PHENYLMETHYL]BENZAMIDE, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SNCA, CHRNA10, CHRNA5 | KEAP1 2901/4885NFE2L2 1584/4885CYP3A4 2925/4885 |
| US-20060223802-A1 | Derivatives of N-[phenyl(pyrrolidine-2-yl)methyl]benzamide and N-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics | SNCA, CHRNA10, CHRNA5 | KEAP1 2901/4885NFE2L2 1584/4885CYP3A4 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.